Quantcast
Channel: Drug and Alcohol Advice » Results
Viewing all articles
Browse latest Browse all 9

Alkermes Announces Results From Phase 2 Study Of ALKS 33 In Alcohol Dependence

0
0

Alkermes, Inc. (NASDAQ: ALKS) announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes’ proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 …

alcohol and addiction news


Viewing all articles
Browse latest Browse all 9

Latest Images

Trending Articles





Latest Images